In a medical research project nearly unrivaled in its ambition and scope, volunteers worldwide are rolling up their sleeves to receive experimental vaccines against the coronavirus — only months after the virus was identified.

Companies like Inovio and Pfizer have begun early tests of candidates in people to determine whether their vaccines are safe. Researchers at the University of Oxford in England are testing vaccines in human subjects, too, and say they could have one ready for emergency use as soon as September.

Moderna on Monday announced encouraging results of a safety trial of its vaccine in eight volunteers. There were no published data, but the news alone kindled hopes and sent the company’s stock soaring….

Read the full The New York Times article